{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"15"},{"groupId":"BG010","value":"44"}],"units":"Participants"}],"groups":[{"description":"Patients receive 1x10\\^6 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG000","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 1"},{"description":"Patients receive 1x10\\^7 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG001","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 2"},{"description":"Patients receive 1x10\\^8 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG002","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 3"},{"description":"Patients receive 1x10\\^9 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG003","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 4"},{"description":"Patients receive 1x10\\^10 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG004","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 5"},{"description":"Patients receive 1x10\\^11 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"BG005","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 6"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then (Stage 1 MTD/100=10\\^7) MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"BG006","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 1"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then 3 x 10\\^7 MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"BG007","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 2"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then 9 x 10\\^7 MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"BG008","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 3"},{"description":"Patients receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"BG009","title":"Phase II (Acetaminophen + Benadryl + MV-NIS)"},{"description":"Total of all reporting groups","id":"BG010","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"59","upperLimit":"66","value":"64"},{"groupId":"BG001","lowerLimit":"57","upperLimit":"68","value":"66"},{"groupId":"BG002","lowerLimit":"43","upperLimit":"74","value":"51"},{"groupId":"BG003","lowerLimit":"63","upperLimit":"82","value":"65"},{"groupId":"BG004","lowerLimit":"56","upperLimit":"65","value":"63"},{"groupId":"BG005","lowerLimit":"49","upperLimit":"65","value":"59"},{"groupId":"BG006","lowerLimit":"49","upperLimit":"81","value":"62"},{"groupId":"BG007","lowerLimit":"59","upperLimit":"65","value":"60"},{"groupId":"BG008","lowerLimit":"59","upperLimit":"71","value":"65"},{"groupId":"BG009","lowerLimit":"40","upperLimit":"72","value":"59"},{"groupId":"BG010","lowerLimit":"40","upperLimit":"82","value":"60"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"18"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"26"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"13"},{"groupId":"BG010","value":"42"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"9"},{"groupId":"BG010","value":"23"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"15"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"6"}],"title":"2"}]}],"description":"Eastern Cooperative Oncology Group PS Scale: 0)Fully active, able to carry on all pre-disease performance without restriction; 1)Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2)Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3)Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4)Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Phase II Cohort A and Phase II Cohort B were combined for this analysis due to accrual terminating early in Cohort B."}